Premium
Biologics in oral medicine: oral Crohn’s disease and orofacial granulomatosis
Author(s) -
O’Neill ID,
Scully C
Publication year - 2012
Publication title -
oral diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.953
H-Index - 87
eISSN - 1601-0825
pISSN - 1354-523X
DOI - 10.1111/j.1601-0825.2012.01918.x
Subject(s) - medicine , infliximab , crohn's disease , disease , adverse effect , oral medicine , malignancy , dermatology , burning mouth syndrome , stomatitis , tumor necrosis factor alpha , oral and maxillofacial pathology , intensive care medicine , dentistry
Oral Diseases (2012) 18 , 633–638 Antitumour necrosis factor (TNF‐α) therapy has a potential to benefit patients with oral lesions of Crohn’s disease (CD) and patients with orofacial granulomatosis (OFG). The most appropriate use would appear to be in patients with severe or multisystem features, where other available agents have failed or have been associated with adverse effects. TNF‐α antagonists (infliximab in particular) have a role in the management of orofacial CD and OFG, but potential adverse effects of TNF‐α antagonists include acute infusion reactions, infection and increased risk of malignancy. Thus, a full risk–benefit analysis is indicated, with patient selection, use and subsequent monitoring coordinated with gastroenterologists with appropriate training and experience in biological therapies.